Epigenetic modifications of DNA and RNA in Alzheimer's disease.
Alzheimer’s disease
DNA methylation
RNA modifications
circRNAs
epigenetics
lncRNAs
miRNAs
non-coding RNAs
Journal
Frontiers in molecular neuroscience
ISSN: 1662-5099
Titre abrégé: Front Mol Neurosci
Pays: Switzerland
ID NLM: 101477914
Informations de publication
Date de publication:
2024
2024
Historique:
received:
08
03
2024
accepted:
15
04
2024
medline:
10
5
2024
pubmed:
10
5
2024
entrez:
10
5
2024
Statut:
epublish
Résumé
Alzheimer's disease (AD) is a complex neurodegenerative disorder and the most common form of dementia. There are two main types of AD: familial and sporadic. Familial AD is linked to mutations in amyloid precursor protein (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2). On the other hand, sporadic AD is the more common form of the disease and has genetic, epigenetic, and environmental components that influence disease onset and progression. Investigating the epigenetic mechanisms associated with AD is essential for increasing understanding of pathology and identifying biomarkers for diagnosis and treatment. Chemical covalent modifications on DNA and RNA can epigenetically regulate gene expression at transcriptional and post-transcriptional levels and play protective or pathological roles in AD and other neurodegenerative diseases.
Identifiants
pubmed: 38726308
doi: 10.3389/fnmol.2024.1398026
pmc: PMC11079283
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1398026Informations de copyright
Copyright © 2024 Martinez-Feduchi, Jin and Yao.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.